317 related articles for article (PubMed ID: 33338537)
1. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis.
Klaeschen AS; Nümm TJ; Herrmann N; Leib N; Maintz L; Sakai T; Wenzel J; Bieber T
J Allergy Clin Immunol; 2021 Jun; 147(6):2202-2212.e8. PubMed ID: 33338537
[TBL] [Abstract][Full Text] [Related]
2. Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice.
Jin W; Huang W; Chen L; Jin M; Wang Q; Gao Z; Jin Z
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544712
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.
Fridman JS; Scherle PA; Collins R; Burn T; Neilan CL; Hertel D; Contel N; Haley P; Thomas B; Shi J; Collier P; Rodgers JD; Shepard S; Metcalf B; Hollis G; Newton RC; Yeleswaram S; Friedman SM; Vaddi K
J Invest Dermatol; 2011 Sep; 131(9):1838-44. PubMed ID: 21677670
[TBL] [Abstract][Full Text] [Related]
4. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
5. JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis.
Wu J; Li L; Zhu Q; Zhang T; Miao F; Cui Z; Dong G; Tai Z; Chen Z
Biomed Pharmacother; 2024 Feb; 171():116167. PubMed ID: 38262152
[TBL] [Abstract][Full Text] [Related]
6. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
8. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
Ferreira S; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
[TBL] [Abstract][Full Text] [Related]
9. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
Parampalli Yajnanarayana S; Stübig T; Cornez I; Alchalby H; Schönberg K; Rudolph J; Triviai I; Wolschke C; Heine A; Brossart P; Kröger N; Wolf D
Br J Haematol; 2015 Jun; 169(6):824-33. PubMed ID: 25824483
[TBL] [Abstract][Full Text] [Related]
10. IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis.
Bao L; Shi VY; Chan LS
Mol Immunol; 2012 Feb; 50(1-2):91-7. PubMed ID: 22226123
[TBL] [Abstract][Full Text] [Related]
11. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C; Yanagihara S; Otsuka A
Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.
Zak M; Hanan EJ; Lupardus P; Brown DG; Robinson C; Siu M; Lyssikatos JP; Romero FA; Zhao G; Kellar T; Mendonca R; Ray NC; Goodacre SC; Crackett PH; McLean N; Hurley CA; Yuen PW; Cheng YX; Liu X; Liimatta M; Kohli PB; Nonomiya J; Salmon G; Buckley G; Lloyd J; Gibbons P; Ghilardi N; Kenny JR; Johnson A
Bioorg Med Chem Lett; 2019 Jun; 29(12):1522-1531. PubMed ID: 30981576
[TBL] [Abstract][Full Text] [Related]
13. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
Kim BS; Howell MD; Sun K; Papp K; Nasir A; Kuligowski ME;
J Allergy Clin Immunol; 2020 Feb; 145(2):572-582. PubMed ID: 31629805
[TBL] [Abstract][Full Text] [Related]
14. FcepsilonRI engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro.
Novak N; Valenta R; Bohle B; Laffer S; Haberstok J; Kraft S; Bieber T
J Allergy Clin Immunol; 2004 May; 113(5):949-57. PubMed ID: 15131579
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
16. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.
Zhang Y; Liang R; Chen CW; Mallano T; Dees C; Distler A; Reich A; Bergmann C; Ramming A; Gelse K; Mielenz D; Distler O; Schett G; Distler JHW
Ann Rheum Dis; 2017 Aug; 76(8):1467-1475. PubMed ID: 28478401
[TBL] [Abstract][Full Text] [Related]
17. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
18. Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.
Curran SA; Shyer JA; St Angelo ET; Talbot LR; Sharma S; Chung DJ; Heller G; Hsu KC; Betts BC; Young JW
Cancer Immunol Res; 2017 Jan; 5(1):52-60. PubMed ID: 27923824
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
